Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

A Multicenter, Open-label, Dose-finding and Dose-expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.

Inclusion Criteria:

• Fully understand the study and voluntarily sign the informed consent form.
• Female 18-75 years of age;
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• Histologically or cytologically confirmed advanced cervical cancer, including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.

Exclusion Criteria:

• Patients were deemed unsuitable for participating in the study by the investigator for any reasons.